Clinical application of airway bypass with paclitaxel-eluting stents: Early results  by Cardoso, Paulo F.G. et al.
E
T
C
p
P
G
ETvolving
echnologylinical application of airway bypass with
aclitaxel-eluting stents: Early results
aulo F. G. Cardoso, MD, PhD,a Gregory I. Snell, MD, MBBS, FRACP,b Peter Hopkins, MD,c Gerhard W. Sybrecht, MD,deorgios Stamatis, MD,e Alan W. Ng, MD,f and Philip Eng, MD, FCCP, FACPg
O
a
M
s
o
p
a
6
R
8
f
e
G
s
o
a
i
C
p
D
tDr Cardosobjective: To assess the safety and early clinical results of a multicenter evaluation of
irway bypass with paclitaxel-eluting stents for selected patients with severe emphysema.
ethods: Airway bypass was performed with a fiberoptic bronchoscope in three
teps: identification of a blood vessel–free location with a Doppler probe at the level
f segmental bronchi, fenestration of the bronchial wall, and placement of a
aclitaxel-eluting stent to expand and maintain the new passage between the airway
nd adjacent lung tissue. All adverse events were recorded, as well as 1- and
-month pulmonary function tests and dyspnea index.
esults: Thirty-five patients received the airway bypass procedure with a median of
stents implanted per patient. At 1-month follow-up, statistically significant dif-
erences in residual volume, total lung capacity, forced vital capacity, forced
xpiratory volume, modified Medical Research Council scale, 6-minute walk, and St
eorge’s Respiratory Questionnaire were observed. At the 6-month follow-up,
tatistically significant improvements in residual volume and dyspnea were dem-
nstrated. One death occurred after bleeding during the procedure. Retrospective
nalysis revealed that the degree of pretreatment hyperinflation may be an important
ndicator of which patients achieve the best short- and long-term results.
onclusions: The airway bypass procedure reduces hyperinflation and improves
ulmonary function and dyspnea in selected patients with severe emphysema.
uration of benefit appears to correlate with the degree of pretreatment hyperinfla-
ion. These preliminary clinical results support further evaluation of the procedure.
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EThe irreversible destruction of lung parenchyma in
emphysema is characterized by progressive air space
enlargement within the lung and is associated with
arked enhancement of collateral ventilation. The concept
f collateral ventilation was first introduced by Van Allen,
indskog, and Richter1 in 1930. Collateral ventilation is
nconsequential in normal human lungs; however, in em-
hysematous lungs it can be essential for ventilation distri-
ution beyond the obstructed airways.2 In emphysema, the
esistance of the airways can exceed collateral resistance,
orcing air to flow preferentially through collateral path-
ays, which may ultimately promote the redistribution of
entilation within the lungs.3 Revisiting this concept in
978, Macklem4 proposed its potential clinical applicability
or reducing gas trapping by venting the hyperinflated em-
hysematous lungs through spiracles—the creation of arti-
cial passages from the lung surface to the outside of the
hest. A recent revision of this lung deflation concept pro-
osed bronchial fenestration for venting the emphysematous
ir spaces into the main airway, coining the term “airway
ypass.”5 Airway bypass is the process of creating extra-
natomic passages between the collaterally ventilated pul-
onary parenchyma and larger airways, allowing trapped
as to exit from the lung. This decrease in gas trapping
educes hyperinflation, allowing better chest wall and dia-
hragmatic excursion and therefore improving dyspnea. The
easibility of airway bypass was first tested experimentally on
x vivo explanted native lungs obtained from patients with
mphysema undergoing lung transplantation.6 This study dem-
nstrated an improvement in the forced expiratory volumes in
and 5 seconds (FEV1 and FEV5), thus suggesting airway
ypass as a potential therapeutic option for patients with
arked hyperinflation and severe pulmonary destruction.
hese early clinical feasibility and safety studies in human
ungs5,7 recognized, but did not address, the need to develop
he technology to improve long-term passage patency.
ther laboratory research studied the value of combining
tents with pharmaceuticals to inhibit tissue growth around
he stent.7 This, in turn, resulted in the development of the
aclitaxel-eluting stent, which significantly prolonged stent
atency in animals.8 On the basis of these advances, the
urrent research was undertaken to assess the safety and
hort-term clinical results of the airway bypass procedure
sing paclitaxel-eluting stents. It evaluates the applicability
f the procedure to a multicenter study while suggesting an
ptimum target group for future clinical studies.
atients and Methods
atients with emphysema were enrolled in the study according to
he following major criteria: computed tomographic scan evidence
f bilateral emphysema; post-bronchodilator residual volume (RV)
20% or more of predicted; post-bronchodilator total lung capacity
TLC) 133% or more of predicted; post-bronchodilator FEV 40%1
r less of predicted or FEV1 of less than1 L; dyspnea scoring of 2 u
The Journal of Thoracicr more according to the modified Medical Research Council
mMRC) scale; arterial oxygen tension of 45 mm Hg or more on
oom air; and subjects who signed an informed consent form, were
ompliant, judged not suitable for other interventions, and consid-
red fit to undergo a procedure under general anesthesia. Major
xclusion criteria were the following: inability to walk more than
40 m at level in 6 minutes after pulmonary rehabilitation; pres-
nce of pulmonary hypertension (peak systolic pressure of 45
m Hg or mean pressure of 35 mm Hg) as documented by
-dimensional echocardiogram or right heart catheterization; any
revious pulmonary resection; coronary artery disease with an-
ina; history of myocardial infarction within 6 months or stroke
ess than 1 year before the procedure; insulin-dependent diabetes;
nequivocal lung cancer or the presence of suspicious pulmonary
odule/infiltrate; large bullae; ventilator dependence; alpha-1 an-
itrypsin deficiency; coagulation disorder; steroid therapy of 20 mg
rednisone or more per day; unequivocal and symptomatic bron-
hiectasis; and 3 or more respiratory infections requiring hospital-
zation within the past 12 months. Subjects who met the criteria
nderwent a pulmonary rehabilitation program of 16 to 20 sessions
ver 6 to 10 weeks, ending no greater than 6 weeks before the
rocedure. Rehabilitation resumed after the procedure for up to 8
eeks and was then encouraged but not required. Within 24 to 48
ours before the procedure, all subjects underwent a chest com-
uted tomographic scan, spirometry, body plethysmography, and
yspnea scoring (baseline measurements). Subjects received intra-
enous antibiotics starting on arrival at the operating room. The
irway bypass procedure was performed with the patient under
eneral anesthesia with orotracheal intubation and controlled me-
hanical ventilation. The Exhale Emphysema Treatment System
Broncus Technologies, Inc, Mountain View, Calif) has 4 compo-
ents: (1) the Exhale Doppler Probe, which is a catheter with a
.4-mm ultrasonic Doppler transducer at the distal tip; (2) the
xhale Doppler Processing Unit, which amplifies the sounds of the
oppler probe; (3) the Exhale Transbronchial Dilation Needle,
hich is a combination 25-gauge needle and 2.5-mm dilation
alloon catheter for passage creation and dilation; and (4) the
xhale Drug-Eluting Stent (3.3-mm inner diameter, 5.3-mm outer
iameter, 2 mm in length) with paclitaxel embedded within the
ilicone layer mounted on a delivery balloon catheter (Figure 1).
ll these catheters were designed to pass through the 2 mm or
arger working channel of a flexible bronchoscope. The system
Abbreviations and Acronyms
COPD  chronic obstructive pulmonary disease
FEV1, FEV5  forced expiratory volumes in 1 and 5
seconds
FVC  forced vital capacity
6MW  6-minute walk
mMRC modified Medical Research Council
NETT  National Emphysema Treatment Trial
RV  residual volume
SGRQ  St George’s Respiratory Questionnaire
TLC  total lung capacityses a standard, commercially available inflation syringe to inflate
and Cardiovascular Surgery ● Volume 134, Number 4 975
t
f
w
l
s
f
(
a
h
t
i
r
fi
w
F
a
c
m
t
a
3
q
b
r
S
S
f
b
S
n
a
e
p
b
2
p
R
A
p
1
(
h
p
r
f
h
a
s
b
b
p
r
D
e
a
T
c
f
r
.
t
(
Evolving Technology Cardoso et al
9
EThe balloons on the balloon catheters. Airway bypass was per-
ormed in a single session with a flexible bronchoscope. Efforts
ere made to place a minimum of 2 stents in each upper and lower
obe bilaterally. The middle lobe was not treated. Creation of each
tented passage required 3 steps: (1) identification of a blood vessel–
ree location with a Doppler probe at the level of segmental bronchi;
2) fenestration of the bronchial wall using the transbronchial needle
nd dilating balloon; and (3) placement of a paclitaxel-eluting stent to
old the passage open. After stent placement, the subject was allowed
o recover from anesthesia, a routine chest radiograph was performed
n the recovery room, and the subject was returned to the hospital
oom the same day. Intravenous antibiotics were continued for the
rst 24 hours after the procedure until discharge from the hospital,
hen they were switched to an oral route for 7 consecutive days.
ollow-up visits were scheduled for 30, 60, 90, 135, and 180 days
fter the procedure. Parameters measured were RV, TLC, forced vital
apacity (FVC), and FEV1. Key functional measurements were
MRC, 6-minute walk (6MW), and St George’s Respiratory Ques-
ionnaire (SGRQ). Safety was assessed through the solicitation of
dverse event reports. Safety stopping rules included the following:
% procedure-related death; 30% postprocedure pneumothorax re-
uiring chest tube drainage for more than 7 days; 3% pulmonary
leeding requiring transfusion; and 15% worsened ventilatory status
esulting in the need for mechanical ventilation.
tatistical Analysis
tatistical analysis included several summary statistics
or changes in the following parameters with respect to
aseline: RV, TLC, FVC, FEV1, mMRC, 6MW, and
GRQ. The descriptive statistics included the number of
onmissing values, mean, and standard deviation at the 1-
nd 6-month visits. The statistical significance of differ-
nces from baseline was assessed by a 2-sided t test that
aired visit values with baseline values. The median p
76 The Journal of Thoracic and Cardiovascular Surgery ● Octoaseline RV/TLC ratio was used to stratify subjects into
groups to assess impact of airway bypass on the test
arameters at 6 months.
esults
total of 35 subjects at 7 centers completed the airway bypass
rocedure between July 2004 and October 2005. There were
9 men and 16 women with ages between 45 to 81 years
average 62 years). The majority of subjects (33/35; 94%) had
omogeneous emphysema. A total of 264 stents were im-
lanted successfully (median of 8 stents per subject, with a
ange of 2 to 12 stents). Three additional subjects were selected
or, but did not complete, the procedure. One subject did not
ave stents implanted due to the abundance of blood vessels
djacent to the airway walls as detected by Doppler. In another
ubject the thickness of the airways prevented stents from
eing implanted. One death occurred after intraoperative
leeding during treatment (2.6% of all subjects; 0.4% of all
assages made). At the time, this triggered the safety stopping
ules for the study. The study was resumed after an extensive
ata and Safety Monitoring Board investigation, which gen-
rated several modifications. Mean baseline versus 1-month
nd 6-month follow-up measurements are listed in Table 1.
he mean values for all measurements listed showed statisti-
ally significant improvement between baseline and 1-month
ollow-up. At 6 months there was a statistically significant
eduction in RV (400 mL; P .04) and dyspnea (0.5; P
025).
Subjects were divided into 2 groups, based on whether
heir baseline RV/TLC ratio was above or below the median
0.67) for the entire cohort. Tables 2 and 3 show the test
Figure 1. Devices used for airway by-
pass: A, Exhale Doppler Probe; B, Ex-
hale Transbronchial Balloon Dilation
Needle; C, Exhale Drug-Eluting Stent
mounted on delivery catheter; D, Ex-
hale Drug-Eluting Stent deployed.arameters at baseline, 1, and 6 months for subjects above
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ETnd below the median, respectively. In subjects with base-
ine RV/TLC above the median, RV is reduced by 1040 mL
16.2%; P  .001) at 1 month and 870 mL (14%; P 
022) at 6 months. In addition, at 6 months FVC improved
y 17% from baseline, which, while not statistically signif-
cant, is higher than the 12% improvement that has been
dentified as clinically significant.9 For subjects with RV/
LC at and below the median, RV (400 mL; P  .048),
ABLE 1. Average values for all subject groups at follow-
arameter Baseline (n  36) 1 Month
V (L) 5.34  1.13 4.85 0.97 
LC (L) 7.80  1.27 7.69 1.18 
VC (L) 2.30  0.80 2.51 0.77
EV1 (L) 0.74 0.19 0.79 0.27
MRC (points) 2.7 0.7 2.0 0.9
MW (m) 340.9 103.1 378.0 114.2
GRQ (points) 57.8 14.9 53.1 16.8
ata are mean  standard deviation. L, liters; m, meters; RV, residual volu
olume in 1 second; mMRC, modified Medical Research Council; 6MW,,
ercent change from baseline reported for RV, percent change from base
values are derived from a 2-tailed paired t test for differences from bas
ABLE 2. Results for patients with baseline RV/TLC above
arameter Baseline (n  18) 1 Month (n  16)
V (L) 5.92 1.21 5.09 1.10 
LC (L) 7.80 1.38 7.41 1.23 
VC (L) 1.78 0.46 2.08 0.50
EV1 (L) 0.64 0.16 0.70 0.24
MRC (points) 2.7 0.8 2.0 1.0
MW (m) 307.4 106.8 349.7 129.9
GRQ (points) 57.1 15.3 49.9 19.4
ata are mean  standard deviation. L, liters; m, meters; RV, residual volu
olume in one second; mMRC, modified Medical Research Council; 6MW
ercent change from baseline reported for RV, percent change from base
values are derived from a 2-tailed paired t test for differences from bas
ABLE 3. Results for patients with baseline RV/TLC at and
arameter Baseline (n  18) 1 Month
V (L) 4.77 0.68 4.55  0.71 
LC (L) 7.80 1.18 8.03  1.05 
VC (L) 2.81 0.75 2.99  0.73
EV1 (L) 0.85 0.17 0.90  0.28
MRC (points) 2.6 0.7 2.1  0.9
MW (m) 374.3 90.1 410.4 86.7
GRQ (points) 58.6 15.0 56.5  13.5
ata are mean  standard deviation. L, liters; m, meters; RV, residual volu
olume in 1 second; mMRC, modified Medical Research Council; 6MW, 6-m
hange from baseline reported for RV, percent change from baseline for T
re derived from a 2-tailed paired t test for differences from baseline. AvVC (11.1%; P  .026) and 6MW (28.6; P  .021) had a l
The Journal of Thoracictatistically significant improvement at 1 month, but none of
he benefits were maintained at 6 months, with most param-
ters returning to near or below baseline.
Adverse events and complications are summarized in
able 4. Of the 38 treated subjects, 3 (7.9%) experienced
ntraoperative serious adverse events, including 1 (2.6%)
eath that was a consequence of major bleeding into the
irway. All other bleeding events were minor and controlled
me points
nge (P value)* 6 Months Change (P value)*
, 12.4% (.001) 4.98 1.25 0.40 L, 6.6% (.040)
, 4.3% (.017) 7.59 1.48 0.25 L, 3.0% (.118)
.2% (.001) 2.31 0.74 8.4% (.332)
.3% (.038) 0.73  0.23 0.6% (.879)
0.6 (.003) 2.2 1.1 0.5 (.025)
37.2 (.001) 326.7  122.3 12.0 (.297)
4.7 (.008) 56.6 17.2 1.8 (.335)
LC, total lung capacity; FVC, forced vital capacity; FEV1, forced expiratory
ute walk; SGRQ, St George’s Respiratory Questionnaire. *Absolute and
r TLC, FVC, and FEV1, and absolute change for mMRC, 6MW, and SGRQ.
. Average changes only include patients with data for 1 or 6 months.
median of 0.67
nge (P value)* 6 Months Change (P value)*
L, 16.2% (.001) 5.20 1.56 0.87 L, 14.1% (.022)
L, 7.1% (.016) 7.45 1.62 0.46 L, 5.6% (.120)
22.6% (.006) 2.01  0.56 17.8% (.065)
7.9% (.113) 0.67  0.25 4.1% (.396)
0.7 (.007) 2.2 1.2 0.5 (.035)
44.7 (.002) 306.4  121.8 1.0 (.948)
7.1 (.007) 52.4  18.7 4.7 (.100)
LC, total lung capacity; FVC, forced vital capacity; FEV1, forced expiratory
inute walk; SGRQ, St George’s Respiratory Questionnaire. *Absolute and
r TLC, FVC, and FEV1, and absolute change for mMRC, 6MW, and SGRQ.
. Average changes only include patients with data for 1 or 6 months.
ow the median of 0.67
nge (P value)* 6 Months Change (P value)*
L, 7.7% (.048) 4.78 0.86 0.03 L, 0.4% (.723)
L, 0.9% (.569) 7.72 1.38 0.05 L, 0.6% (.718)
1.1% (.026) 2.67 0.79 2.9% (.285)
6.7% (.191) 0.81 0.198 3.6% (.301)
0.5 (.120) 2.1  1.1 0.5 (.216)
28.6 (.021) 349.5 122.6 24.4 (.170)
2.1 (.374) 61.6  14.3 1.7 (.468)
LC, total lung capacity; FVC, forced vital capacity; FEV1, forced expiratory
alk; SGRQ, St George’s Respiratory Questionnaire. *Absolute and percent
C, and FEV1, and absolute change for mMRC, 6MW, and SGRQ. P values
changes only include patients with data for 1 or 6 months.up ti
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Evolving Technology Cardoso et al
9
EThe other serious adverse events were pneumomediastinum
ith subcutaneous emphysema, which occurred in 2 (5.3%)
f 38 subjects. One of these events was treated medically
using oxygen therapy, analgesics, and bronchodilators),
nd the other resolved spontaneously without intervention.
ostoperative serious adverse events occurred in 22 (59.4%)
f 37 subjects. The 2 most frequently encountered, related
erious adverse events were chronic obstructive pulmonary
isease (COPD) exacerbations and infection. As is widely
nown, exacerbations are largely a feature of moderate-to-
evere COPD. Sixteen episodes of COPD exacerbation oc-
urred in 12 (32.4%) of 37 treated subjects. However, only
of these events occurred within 1 month of treatment and
he remainder occurred between 39 and 236 days after
reatment (average 144 days). Respiratory infection oc-
urred in 10 (27%) of 37 treated subjects, 5 (13.5%) of these
ccurred within the first week of treatment, and all were
esolved medically. Other related serious adverse events re-
orted as single events included hypercapnia, respiratory fail-
re, and an adverse reaction to naloxone after a scheduled
ollow-up bronchoscopic examination. Unrelated serious car-
iac events were reported in 1 subject, in whom ischemic heart
isease and unstable angina developed. One subject had a
owel obstruction that required laparotomy and ultimately died
weeks after the operation as a result of infectious complica-
ions and sepsis. This event occurred 53 days after airway
ypass treatment and death was found to be unrelated to the
rocedure. Three (8.5%) other subjects were lost to fol-
ow-up over the 6-month period.
Although stent potency is not a primary focus of this
tudy, it is an important factor that could affect the clinical
esults. Follow-up bronchoscopic examinations assessed
tent patency in a subset of patients. At 6 months, when 26
ite locations were reviewed bronchoscopically, 18 (69%)
tents were judged to be patent (Figure 2).
iscussion
he management of emphysema poses a difficult challenge
or the medical community inasmuch as the disease progres-
ively deprives patients of their ability to perform activities of
ABLE 4. Serious adverse events recorded after the airwa
erious adverse event N/total (%)
ntraoperative airway bleeding 1/38 (2.6%)
ntraoperative pneumomediastinum 2/38 (5.3%)
OPD exacerbation 12/37 (32.4%)
espiratory infection 10/37 (27%)
nstable angina* 1/37 (2.7%)
owel obstruction* 1/37 (2.7%)
, number of patients who had serious adverse events; Early adverse even
fter the procedure. *Found to be unrelated to the airway bypass procedaily living and is associated with repeated exacerbations. o
78 The Journal of Thoracic and Cardiovascular Surgery ● Octourrent medical therapies include bronchodilators, steroids,
nd antibiotics, all directly or indirectly designed to reduce
irway resistance to improve respiratory flows and reduce
yperinflation. The long-term results from the National Em-
hysema Treatment Trial (NETT) confirmed that lung vol-
me reduction surgery, by reducing hyperinflation, can sig-
ificantly benefit certain patients with emphysema.10 This
as led to exploring less invasive, endoscopic procedures that
ight produce similar results. “Bronchoscopic lung-volume
eduction” with 1-way valves is being evaluated for patients
ith severe heterogeneous emphysema.8,11,12 However, pa-
ients with severe homogeneous emphysema are generally not
ligible for treatment modalities other than medical manage-
ent and, in infrequent instances, lung transplantation. Such
atients might therefore benefit from a procedure that does
ot require surgical intervention, reduces hyperinflation,
nd palliates dyspnea. Airway bypass has been proposed as
procedure that might meet these requirements. It is based
n the concept that dynamic distal airway resistance is
reatly enhanced in emphysema concurrent with increased
ollateral ventilation.6,13 Choong and associates14 demon-
igure 2. Image of an implanted stent at 6-month follow-up fiber-
pass procedure
rly Late Outcome
— One death (2.6%)
— Resolved spontaneously (no drainage)
14 Resolved clinically
5 Resolved clinically
1 Controlled clinically
— One death (2.7%)
than 30 days after the procedure; Late adverse event, more than 30 daysy by
Ea
1
2
2
5
—
1
t, lessptic bronchoscopic examination.
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ETtrated in an animal model that paclitaxel-eluting silicone-
overed metal stents significantly extended patency. These
ndings supported the assumption that paclitaxel-eluting
tents could be beneficial for the airway bypass procedure
nd prompted this initial human study. Paclitaxel is a che-
otherapeutic agent administered systemically at dosages
n the range of 135 to 300 mg/m2 with acceptable patient
olerance. Coronary and airway bypass paclitaxel-eluting
tents are loaded with approximately 400 g of paclitaxel/
tent, which is a small fraction of the systemic dose deliv-
red for chemotherapy.14
There is strong evidence from the results (Table 1) that
he mechanism of action by which airway bypass works is
reduction in hyperinflation, measured by a reduction in
ung volumes including RV and TLC. The average pretreat-
ent RV in this study population was 5.34 L (257% of
redicted normal), which illustrates the severity of gas trap-
ing present in these subjects. Given that the procedure
elies on the abundant collateral ventilation found in se-
erely emphysematous lungs, airway bypass would be ex-
ected to reduce gas trapping the most in patients with
xtensive hyperinflation. A statistically significant reduction
n hyperinflation, as reflected by RV, was observed through-
ut the 6-month follow up. This paralleled improvement in
yspnea. However, exercise capacity improvement, as mea-
ured by 6MW, was not sustained at 6 months. The cessa-
ion of the initial exercise capacity improvement might be
ue at least in part to the cessation of the perioperative
ehabilitation program at 8 weeks. The benefits of rehabil-
tation before treatment were described in a report from the
ETT, which demonstrated its effectiveness in preparing
nd selecting subjects for lung volume reduction surgery.15
e therefore hypothesized that the use of rehabilitation
or all subjects selected for airway bypass would be
eneficial, inasmuch as their muscular reconditioning is
mproved by the program, and which in turn allows
urther improvement in their overall condition, enhancing
he benefit received from reducing hyperinflation by the
irway bypass procedure.
The air flow measurement FEV1 has been used as a
tandard outcome measure in both the NETT10 and in bron-
hoscopic lung volume reduction8 studies. However, the
ack of significant change in FEV1 after airway bypass, in
he presence of significantly improved dyspnea and RV
eduction in this study, suggests the effect produced by
irway bypass is not reflected in the rapid exhalation as
easured by FEV1, but in reduced gas trapping as measured
y RV. Indeed, FEV1 has not been found to correlate with
atient-centered outcomes such as exercise tolerance, dys-
nea, or health-related quality of life, as opposed to hyper-
nflation, which is directly associated with dyspnea and
xercise limitation.16 Studies with short- and long-acting
ronchodilators have shown that substantial reduction in t
The Journal of Thoracicyperinflation in patients with COPD may be followed by
ather small changes in FEV1.17 A recent study involving
ndobronchial valves for emphysema also has failed to
emonstrate significant changes in FEV1.18 The reduction in
yperinflation has been shown to correlate better with ex-
rcise endurance and dyspnea ratings than with spirometry
arameters.19 The reduction of benefit observed between 1
nd 6 months after the airway bypass procedure could be
ue to one or more factors, which include patient selection
riteria, suboptimal selection of sites for stent placement,
tent patency, or other yet-to-be-determined factors. Inas-
uch as airway bypass relies primarily on abundant collat-
ral ventilation, which is greatly enhanced in patients with
evere emphysema, subjects with severely hyperinflated
ungs are, theoretically, the most likely to benefit from the
rocedure. Retrospective analysis of our patients using RV/
LC ratios above and below median (Tables 2 and 3)
uggests that the degree of pretreatment hyperinflation may
e an important factor in indicating patients who are most
ikely to achieve long-term benefits. Analogous to other
nterventions for emphysema, the degree of chest remodel-
ng and diaphragmatic motion can also play a role in the
ssessment of outcome, and studies are currently being
arried out to investigate new methods. On the basis of these
arly results, we can anticipate that the target population for
uture studies and clinical application of this procedure will
ave to include patients with severe hyperinflation.
The ideal number and location of stents to place is yet to
e determined. Initial attempts to implant approximately 10
tents were based on the study of excised human lungs.6
nalysis of the current data shows no correlation between
he number of stents placed and the degree of improvement
n RV at any time point. The ideal number and location of
tent placement remains a focus of ongoing studies.
Analysis of the limited bronchoscopic evaluation at 6
onths shows that paclitaxel-eluting stents seem to be as-
ociated with extended stent patency. These clinical results
ere consistent with the work reported by Choong and
ssociates,14 which showed that 65% of paclitaxel-eluting
tents in animals were patent at 12 weeks. Stent patency also
emains a focus of ongoing studies. New approaches to
apping and computed tomographic evaluation of the stents
ay facilitate this work.
The major intraoperative risks involved in airway bypass
nclude pneumothorax and airway bleeding. No instances of
neumothorax occurred and all but one bleeding episode
as controlled locally with instillation of cold saline and
pinephrine solution. The major bleeding episode that re-
ulted in the subject’s death was attributable to stent placement
way from the original “quiet spot” identified by the Doppler
robe. An extensive investigation conducted by the study’s
ata and Safety Monitoring Board, including a video review ofhe procedure regarding this event, resulted in several recom-
and Cardiovascular Surgery ● Volume 134, Number 4 979
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ETendations. Modifications incorporated into the study in-
luded a stand-by balloon blocker placed into the main bron-
hus during every procedure and the repeat Doppler scanning
f the passages created and dilated by the needle–balloon
evice before deploying the stent.
The present study was designed to demonstrate the ap-
licability of airway bypass to a multicenter study and proof
f concept of the airway bypass procedure using the
aclitaxel-eluting stent in subjects with moderate-to-severe
mphysema. The subjects in this study had more severe
isease (greater RV and TLC, shorter 6MW, less quality of
ife, and a higher percentage of homogeneous emphysema,
4% vs 46%, respectively) than those in the NETT. By
etrospective analysis, the most statistically significant re-
ults were observed in patients with the greatest degree of
retreatment hyperinflation.
In conclusion, early results of the airway bypass proce-
ure using a paclitaxel-eluting stent in a multicenter study
ave been shown to reduce hyperinflation and dyspnea and
o improve pulmonary function in subjects with severe
mphysema, especially in those with severe hyperinflation.
he clinical improvements demonstrated in these prelimi-
ary clinical results support further investigation of the
irway bypass procedure. Questions about patient selection,
he optimal placement of the stents, and stent patency pro-
ide direction for further study.
We acknowledge Joel D. Cooper, MD, Julia S. Rasor, MS, and
erese Bogucki for analysis and peer review of this manuscript,
eter Macklem, MD, Bonnie Stearns, and Corey Powell for the
tatistical analysis, the Broncus staff, and Broncus Technologies
or sponsoring this study and for providing the equipment and
echnical support.
eferences
1. Van Allen C, Lindskog G, Richter H. Gaseous interchange between
adjacent lung lobules. Yale J Biol Med. 1930;2:297-300.
2. Menkes H, Traystman R, Terry P. Collateral ventilation. Fed Proc.
1979;38:22-6.
3. Terry PB, Traystman RJ, Newball HH, Batra G, Menkes HA. Collat-
eral ventilation in man. N Engl J Med. 1978;298:10-5.
4. Macklem PT. Collateral ventilation. N Engl J Med. 1978;298:49-50.
5. Rendina EA, De Giacomo T, Venuta F, Coloni GF, Meyers BF,
Patterson GA, et al. Feasibility and safety of the airway bypass
procedure for patients with emphysema. J Thorac Cardiovasc Surg.
2003;125:1294-9.
6. Lausberg HF, Chino K, Patterson GA, Meyers BF, Toeniskoetter PD,
Cooper JD. Bronchial fenestration improves expiratory flow in em-
physematous human lungs. Ann Thorac Surg. 2003;75:393-7.
7. Choong CK, Haddad FJ, Gee EY, Cooper JD. Feasibility and safety of
airway bypass stent placement and influence of topical mitomycin C
on stent patency. J Thorac Cardiovasc Surg. 2005;129:632-8.
8. Wan IY, Toma TP, Geddes DM, Snell G, Williams T, Venuta F, et al.
Bronchoscopic lung volume reduction for end-stage emphysema: re-
port on the first 98 patients. Chest. 2006;129:518-26.
9. ATS. Lung function testing: selection of reference values and inter-
pretative strategies. American Thoracic Society. Am Rev Respir Dis.
1991;144:1202-18.0. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A,
et al. A randomized trial comparing lung-volume-reduction surgery u
80 The Journal of Thoracic and Cardiovascular Surgery ● Octowith medical therapy for severe emphysema. N Engl J Med.
2003;348:2059-73.
1. Snell GI, Holsworth L, Borrill ZL, Thomson KR, Kalff V, Smith JA,
et al. The potential for bronchoscopic lung volume reduction using
bronchial prostheses: a pilot study. Chest. 2003;124:1073-80.
2. Venuta F, de Giacomo T, Rendina EA, Ciccone AM, Diso D, Perrone
A, et al. Bronchoscopic lung-volume reduction with one-way valves in
patients with heterogenous emphysema. Ann Thorac Surg. 2005;79:
411-6.
3. Brenner M, Hanna NM, Mina-Araghi R, Gelb AF, McKenna RJ Jr,
Colt H. Innovative approaches to lung volume reduction for emphy-
sema. Chest. 2004;126:238-48.
4. Choong CK, Phan L, Massetti P, Haddad FJ, Martinez C, Roschak E,
et al. Prolongation of patency of airway bypass stents with use of
drug-eluting stents. J Thorac Cardiovasc Surg. 2006;131:60-4.
5. Ries AL, Make BJ, Lee SM, Krasna MJ, Bartels M, Crouch R, et al.
The effects of pulmonary rehabilitation in the national emphysema
treatment trial. Chest. 2005;128:3799-809.
6. Cooper CB. The connection between chronic obstructive pulmonary
disease symptoms and hyperinflation and its impact on exercise and
function. Am J Med. 2006;119:21-31.
7. O’Donnell DE. Is sustained pharmacologic lung volume reduction
now possible in COPD? Chest. 2006;129:501-3.
8. Wood DE, McKenna RJ Jr, Yusen RD, Sterman DH, Ost DE, Spring-
meyer SC, et al. A multicenter trial of an intrabronchial valve for
treatment of severe emphysema. J Thorac Cardiovasc Surg. 2007;133:
65-73.
9. O’Donnell DE, Lam M, Webb KA. Spirometric correlates of improve-
ment in exercise performance after anticholinergic therapy in chronic
obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:
542-9.
iscussion
r Cliff K. Choong (Cambridge, United Kingdom). Dr Cardoso,
ongratulations to you and your co-investigators on this study and
esults. I am glad to see that the good feasibility and safety results
hat were found in the animal studies that we had performed have
een largely translated and reproduced by you and your clinical
nvestigators in this multicenter study. In the animal study that we
ad performed at Washington University, we had found that 65%
f paclitaxel stents were patent at 18 weeks whereas the control
tents were all occluded at 4 weeks. This information was pre-
ented in 2005 before this Association and published in the Janu-
ry 2006 issue of the Journal of Thoracic and Cardiovascular
urgery. I have always been curious about patency in clinical
tudies on patients. On the one hand, it may be that ventilation
hrough the airway bypass stents between the airway and the
estroyed emphysematous lungs may improve the patency rate, but
n the other hand, thick mucus and infection in patients with
OPD may accelerate occlusions of the airway bypass stents. Did
ou and your investigators assess the patency of the airway bypass
tents in your patients? If you did, what were the percentage of
atency and the duration of patency, and how did that correlate
ith the clinical findings?
Second, have you any idea as to what may be the optimal
umber of stents for treating patients with homogenous emphy-
ema?
The last issue concerns collateral ventilation. It seems to me
hat the 1-way valve such as those produced by Emphasys and
piration may be useful in patients with minimal or no collateral
entilation and causing atelectasis of the segments or lobes in
hose areas, whereas the airway bypass stents may be effective and
seful in patients with extensive collateral ventilation. I think there
ber 2007
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ETay be a role in combining both modalities. I would appreciate
our opinion on that.
Dr Cardoso. Thank you very much, Dr Choong, and thanks for
he major contribution you have made. You paved the ground for
his clinical study to be done today with your animal data.
Regarding the number of stents, we participated in three dif-
erent arms of this protocol, and this is the last arm. At the
eginning, the idea was to insert as many stents as possible. In a
ew patients in whom we could not insert many stents owing to
natomic reasons or for the presence of vessels around the airway,
e realized that these patients did as well as the patients who had
eceived many stents. We then concluded that perhaps it is not
ecessary to use too many stents to get results. It became clear that
hat is really necessary is to deflate both lungs.
Regarding patency, unfortunately I cannot provide this infor-
ation right now because this study is still ongoing. We will have
he data on patency when the study is completed in a few months.
hat I have is anecdotal data on the last 2 patients on whom we
id the 6-month follow-up—the last 2 patients we treated in this
rotocol. One of them had the stents completely open, whereas the
ther patient had all the stents closed. We are still trying to figure
ut which factors play a role in stent patency.
Regarding collateral ventilation and its effects, these are dif-
erent things. The valve system and the stents work in different
mphysema patients. If we are talking about homogenous emphy-
ema with very severe destruction in the parenchyma, then these
re probably not the best patients for the valves but for the stents.
ince emphysema is generally a very heterogeneous population,
hose patients who do have destruction, for example, in the upper
obes with target areas could be treated with valves in the upper
obes and the rest of the parenchyma could be treated with stents.
ime will tell about the outcome.
Dr Erino Rendina (Rome, Italy). Again, congratulations, Dr
ardoso, on an excellent presentation. These are, to the best of my
nowledge, the first clinical results published on airway bypass.
ou are to be congratulated on being able to demonstrate benefitso this procedure at intervals as long as 6 months. I would like to s
The Journal of Thoracicsk your opinion on two issues. The first issue is the selection
rocess. I did not see in your presentation anything about the
valuation of the small airway in these patients. I think the status
f the small airway is a very important issue because it has a
elation with the destructive component of emphysema. Would
ou like to comment on that?
The other issue is the deaths that occurred among your patients.
hat stresses an important point. The airway bypass is a surgical
rocedure. In our early experience with airway bypass at the time
hen the stents were not available, we also had an episode of
leeding, but we were able as surgeons to control this very serious
ccurrence, and the patient had no problems. I think it is important
o keep in mind that, though safe, this remains a surgical procedure
hat should be performed by surgeons.
Dr Cardoso. Thank you very much. Dr Rendina is another
ornerstone of this procedure.
Regarding selection, patients who have severe bronchitis prob-
bly are not the best candidates. As a matter of fact, we had 1
atient whose airway was so severely deranged because of bron-
hitis that we could not insert any stents. Furthermore, distal
irway disease is something that could eventually alter this mech-
nism by which airway bypass works, which is ultimately depen-
ent on the enhancement of collateral ventilation. I think one must
e very selective to get good results.
Regarding expertise, I think surgeons and pulmonologists who
an treat massive hemoptysis can do this procedure. That is not an
ssue. The issue is that this has to be done in a surgical environ-
ent with all the equipment needed because it is an invasive
rocedure and must be done by people who are very familiar with
nterventional endoscopy. The regular diagnostic endoscopist
robably needs a lot of training to do this procedure safely.
onetheless, it is a rather straightforward and very safe procedure.
Dr John D. Puskas (Atlanta, Ga). Thank you, Dr Cardoso, for
our landmark study and congratulations on demonstrating for the
rst time in a clinical trial the benefit of endoscopic airway
tenting.
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